The Impact of an Electronic Prescribing Template with Decision Support upon the Prescribing of Subcutaneous Infusions at the End of Life in a Community Setting: A Future Vision for Community Palliative Care.
community care
electronic prescribing
palliative care
pharmacy practice
subcutaneous infusions
Journal
Pharmacy (Basel, Switzerland)
ISSN: 2226-4787
Titre abrégé: Pharmacy (Basel)
Pays: Switzerland
ID NLM: 101678532
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
received:
28
07
2022
revised:
31
08
2022
accepted:
06
09
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
Objectives: To assess the impact of an electronic prescribing template with decision support upon the frequency of prescription errors, guideline adherence (relating to dose ranges), and prescription legality when prescribing continuous subcutaneous infusions (CSCI) in a palliative demographic. Design, setting, and participants: Before-and-after study across a large UK city utilizing local prescribing data taken from patients receiving end-of-life care. Intervention: An electronic prescribing template with decision support. Main outcome measures: The following were assessed: (1) the rate of prescription errors; (2) the proportion of prescriptions specifying a dose range and if the specified range complied with local recommendations; and (3) the proportion of prescriptions specifying legal mixing directions. Results: The intervention was associated with a significant reduction in errors of omission, with all prescriptions clearly stating drug indication, route of administration, drug dose, and infusion duration. The numbers of continuous subcutaneous infusion prescriptions that specified dose ranges were similar at baseline and post-intervention, at 71% (n = 122) and 72% (n = 179), respectively. At baseline, 69% (n = 84) of CSCI prescriptions specifying a dose range were deemed safe, and post-intervention, 97% (n = 173) were determined to be safe. At baseline, mixing directions were not specified correctly on any continuous subcutaneous infusion prescriptions, while post-intervention, such directions were correct on 75% (n = 157; p < 0.05) of the prescriptions. Conclusions: The intervention eliminated errors of omission, ensured the safety of prescribed dose ranges, and improved compliance with legislation surrounding the mixing of multicomponent infusions. Overall, the intervention has the potential to improve patient safety at the end of life and to increase the efficiency of community services.
Identifiants
pubmed: 36136845
pii: pharmacy10050112
doi: 10.3390/pharmacy10050112
pmc: PMC9498806
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Drug Saf. 2009;32(5):379-89
pubmed: 19419233
Int J Physiol Pathophysiol Pharmacol. 2011;3(4):257-65
pubmed: 22162782
Palliat Med. 2019 Feb;33(2):160-177
pubmed: 30513254
Int J Med Inform. 2022 Jul;163:104777
pubmed: 35483130
Palliat Med. 2006 Oct;20(7):661-4
pubmed: 17060264
Int J Qual Health Care. 2005 Feb;17(1):15-22
pubmed: 15668306
Clin Drug Investig. 2021 Aug;41(8):675-683
pubmed: 34213758
Palliat Med. 2015 Jan;29(1):60-70
pubmed: 25070861
Crit Care. 2005 Oct 5;9(5):R516-21
pubmed: 16277713
Postgrad Med J. 2004 Jan;80(939):1-6
pubmed: 14760169
Crit Care. 1998;2(2):73-78
pubmed: 11056713
J Adv Nurs. 2017 Oct;73(10):2385-2394
pubmed: 28423478
Br J Clin Pharmacol. 2009 Jun;67(6):624-8
pubmed: 19594530
BMC Clin Pharmacol. 2009 May 13;9:9
pubmed: 19439066
BMJ Support Palliat Care. 2013 Mar;3(1):91-7
pubmed: 24644333
BMJ Support Palliat Care. 2020 Sep;10(3):343-349
pubmed: 32546559
Int J Palliat Nurs. 2004 Aug;10(8):405-12
pubmed: 15365496
J Pain Symptom Manage. 2001 Jun;21(6):473-80
pubmed: 11397605
Am J Hosp Palliat Care. 2015 Aug;32(5):484-9
pubmed: 24803586
Qual Saf Health Care. 2007 Aug;16(4):279-84
pubmed: 17693676
Am Fam Physician. 2017 Mar 15;95(6):356-361
pubmed: 28318209
Br J Nurs. 2014 Jul 24-Aug 13;23(14):S10, S12-4
pubmed: 25158361